| 5.34 -0.08 (-1.48%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.86 | 1-year : | 8.02 |
| Resists | First : | 5.88 | Second : | 6.86 |
| Pivot price | 5.32 |
|||
| Supports | First : | 5.11 |
Second : | 4.65 |
| MAs | MA(5) : | 5.28 |
MA(20) : | 5.24 |
| MA(100) : | 6.61 |
MA(250) : | 5.88 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 48.1 |
D(3) : | 47.8 |
| RSI | RSI(14): 50 |
|||
| 52-week | High : | 11.67 | Low : | 2.57 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ EPIX ] has closed below upper band by 47.3%. Bollinger Bands are 50.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.5 - 5.52 | 5.52 - 5.55 |
| Low: | 5.08 - 5.12 | 5.12 - 5.15 |
| Close: | 5.28 - 5.33 | 5.33 - 5.38 |
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Wed, 24 Jul 2024
ESSA Pharma Inc. (NASDAQ:EPIX) Shares Sold by BNP Paribas Financial Markets - Defense World
Wed, 17 Jul 2024
Hedge funds investors have a lot riding on ESSA Pharma Inc. (NASDAQ:EPIX) with 40% ownership - Simply Wall St
Sat, 13 Jul 2024
ESSA Pharma (NASDAQ:EPIX) Stock Crosses Below Fifty Day Moving Average of $5.67 - American Banking and Market News
Mon, 08 Jul 2024
ESSA Pharma to Present at the JonesHealthcare Seaside Summit - StockTitan
Wed, 29 May 2024
ESSA Pharma’s Speculative Buy Potential: Masofaniten Promise For Prostate Cancer (EPIX) - Seeking Alpha
Tue, 21 May 2024
Insider Stock Buying Reaches US$709.0k On ESSA Pharma - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 79.1 (%) |
| Shares Short | 1,010 (K) |
| Shares Short P.Month | 844 (K) |
| EPS | -0.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -14.4 % |
| Return on Equity (ttm) | -19.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -8.48 |
| PEG Ratio | 0 |
| Price to Book value | 1.77 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|